Abstract
Importance Cholesteryl ester transfer protein (CETP) inhibition has been associated with decreased risk of new-onset diabetes in past clinical trials exploring their efficacy in cardiovascular disease and can potentially be repurposed to treat metabolic disease. Notably, as an oral drug it can potentially be used to supplement existing oral drugs such as sodium-glucose cotransporter 2 (SGLT2) inhibitors before patients are required to take injectable drugs such as insulin.
Objective To identify whether CETP inhibitors could be used as an oral add-on to SGLT2 inhibition to improve glycemic control.
Design, Setting, and Participants 2×2 factorial Mendelian Randomization (MR) is performed on the general population of UK Biobank participants with European ancestry.
Exposures Previously constructed genetic scores for CETP and SGLT2 function are combined in a 2×2 factorial framework to characterize the associations between joint CETP and SGLT2 inhibition compared to either alone.
Main Outcomes and Measures Glycated hemoglobin and type-2 diabetes incidence.
Results Data on 233,765 UK Biobank participants suggests that individuals with genetic inhibition of both CETP and SGLT2 have significantly lower glycated hemoglobin levels (mmol/mol) than control (Effect size: −0.136; 95% CI: −0.190 to −0.081; p-value: 1.09E-06), SGLT2 inhibition alone (Effect size: −0.082; 95% CI: −0.140 to −0.024; p-value: 0.00558), and CETP inhibition alone (Effect size: −0.08479; 95% CI: −0.136 to −0.033; p-value: 0.00118).
Furthermore, joint CETP and SGLT2 inhibition is associated with decreased incidence of diabetes (log-odds ratio) compared to control (Effect size: −0.068; 95% CI: −0.115 to −0.021; p- value: 4.44E-03) and SGLT2 inhibition alone (Effect size: −0.062; 95% CI: −0.112 to −0.012; p-value: 0.0149).
Conclusions and Relevance Our results suggest that CETP and SGLT2 inhibitor therapy may improve glycemic control over SGLT2 inhibitors alone. Future clinical trials can explore whether CETP inhibitors can be repurposed to treat metabolic disease and provide an oral therapeutic option to benefit high-risk patients before escalation to injectable drugs such as insulin or glucagon-like peptide 1 (GLP1) receptor agonists.
Question Does combined genetic CETP and SGLT2 inhibition confer decreased glycated hemoglobin or diabetes incidence compared to SGLT2 inhibition alone?
Findings In this cohort study, a 2×2 factorial Mendelian randomization analysis on the UK Biobank reveals that combined genetic CETP and SGLT2 inhibition is associated with decreased glycated hemoglobin and diabetes risk compared to both control and SGLT2 inhibition alone.
Meaning Our findings suggest that CETP inhibitors, which are currently in clinical trials to treat cardiovascular disease, can be repurposed to treat metabolic disease in a combination therapy approach with SGLT2 inhibitors.
Competing Interest Statement
BBK is the co-founder of Dock Therapeutics, Inc. JJPK and MHD are co-founders of NewAmsterdam Pharma, B.V.
Funding Statement
BBK acknowledges funding support from Indiana University and NIH R01DK132090.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent prior to data collection. UK Biobank has full ethical approval from the NHS National Research Ethics Service (16/NW/0274). All methods were carried out in accordance with relevant guidelines and regulations. UK Biobank data is available to researchers upon request (https://www.ukbiobank.ac.uk/enable-your-research).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at: https://www.ukbiobank.ac.uk/enable-your-research
